$26.42
Value $994M
CBLL and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$26.42
Value $994M
$282.55
Value $681B
CeriBell (CBLL) has a market value of $994M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, CBLL moved +104.8% and JNJ +47.5%. Dividend yield: CBLL none, JNJ 1.87%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CBLL$994M
JNJ$681B
JNJ is 685 times CBLL
Revenue, 12 months
CBLL$109M
JNJ$99.3B
JNJ is 914 times CBLL
Net income, 12 months
CBLL-$74M
JNJ$16.1B
Operating margin
CBLL-69.8%
JNJ–
ROIC
CBLL-37.2%
JNJ12.4%
49.6 points apart
P/E
CBLL–
JNJ42.3
Dividend yield
CBLL0.0%
JNJ1.9%
1.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CBLL+104.8%
JNJ+47.5%
| Period | CBLLWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +104.8%Price +104.8% | +47.5%Price +44.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CBLLCeriBellJNJJohnson & Johnson
| Price | $26.42 | $282.55 |
|---|---|---|
| Market value | $994M | $681B |
| Enterprise value (EV) | $897M | $708B |
| P/E | – | 42.3 |
| P/E, 5-year median | – | 21.9 |
| P/B | 8.5 | 8.4 |
| EV/EBIT | – | 39.9 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | $109M | $99.3B |
|---|---|---|
| Net income, 12 months | -$74M | $16.1B |
| Free cash flow, 12 months | -$56M | $20.6B |
| Earnings per share, 12 months | -$1.94 | $6.59 |
| Revenue growth, year on year | 36.1% | 6.1% |
| Revenue growth a year, past | +40.3%over 2 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 89.3% | 67.6% |
|---|---|---|
| Operating margin | -69.8% | – |
| Net margin | -68.0% | 16.2% |
| ROIC | -37.2% | 12.4% |
| ROE | -52.3% | 19.7% |
| Cash | $118M | $17.2B |
|---|---|---|
| Total debt | $22M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | -47.4× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($681B) is about 684.7 times CeriBell ($994M), at today's prices.
Since November 14, 2025, CBLL's price moved +104.8% and JNJ's +44.2%. With dividends: CBLL +104.8% (+104.8% a year), JNJ +47.5% (+47.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for CeriBell and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -68.0% for CeriBell and 16.2% for Johnson & Johnson, and the operating margin -69.8% and –. Revenue was $109M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.